Zydus receives final approval from USFDA for Bumetanide Tablets

03 May 2018 Evaluate

Zydus Cadila has received the final approval from the Us Food and Drug Administration (USFDA) to market Bumetanide Tablets USP in the strengths of 0.5 mg, 1 mg, and 2 mg. It is used to treat edema associated with congestive heart failure, hepatic and renal disease, including the Nephrotic Syndrome. The tablets will be manufactured at the group’s manufacturing facility at Baddi.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 185 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×